Comparison of HFNO and FMV on Desaturations During Panendoscopy Under General Anesthesia

February 6, 2024 updated by: David Ferreira, Centre Hospitalier Universitaire de Besancon

Comparison of High-flow Nasal Oxygen Therapy and Face Mask Ventilation on Desaturations During Panendoscopy Under General Anesthesia

Panendoscopy is a common procedure that requires deep and short anesthesia. The main challenge is the sharing of the airway between the anesthesia team and the surgical team. There are several methods to ensure oxygenation during this type of procedure: oro-tracheal intubation, jet ventilation, spontaneous ventilation anesthesia, apneic ventilation with intermittent face mask ventilation. There is no consensus regarding the best airway management technique for this procedure. Regardless of the method chosen to ensure oxygenation during this procedure, the risk of hypoxemia during desaturation episodes is significant.

However, the use of HFNO seems to show a prolongation of apnea time without desaturations (< 90% SpO2) and seems to allow the performance of panendocoscopies.

In the Besançon University Hospital, since 2017, all panendoscopies are performed with HFNO. Before 2017, panendoscopies were performed under face mask ventilation. The main of the study hypothesis is that HFNO brought a gain in terms of safety, especially on the desaturation rate compared to face mask ventilation.

The investigators will carry out a quasi-experimental study comparing two periods. The first period concerns the years 2015-2016. It aims to study patients who had panendoscopies performed under FMV. The second period covers the years 2018-2019. It aims to study patients who had panendoscopies performed under HFNO.

The year 2017 is considered as the washout period necessary to avoid the learning effect of the HFNO introduced during that year.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Currently, there are several strategies to ensure oxygenation during this specific type of ENT management:

  • Mechanical ventilation with oro-tracheal intubation (OTI)
  • face mask ventilation (FMV)
  • Jet ventilation
  • HFNO Each of these methods has advantages and disadvantages, which explains why there are no clear recommendations to date on the preferred anesthesia and oxygenation technique. Regardless of the method chosen, the risks remain significant for the patient, particularly the risk of hypoxemia during a desaturation episode.

In 2017, HFNO was introduced for panendoscopies in the Besançon University Hospital. Before 2017, panendoscopies were mainly perfomed with intermittent face mask ventilation.

The objective of the study is to compare the FMV group (patients receiving panendoscopy and ventilated with FMV during 2015-2016) with the HFNO group (patients receiving panendoscopy and oxygenated with HFNO during 2018-2019) with respect to perprocedural hypoxemia (SpO2<90% for more than 1 minute).

Secondary objectives are to compare complications, use of oro-tracheal intubation, and procedure duration between the two oxygenation methods.

Study Type

Observational

Enrollment (Estimated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Franche Comté
      • Besançon, Franche Comté, France, 25000
        • CENTRE HOSPITALIER UNIVERSITAIRE de BESANCON

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Face Mask Ventilation (FMV) Group :patients who had panendoscopies performed under FMV during the years 2015-2016.

HFNO group :patients who had panendoscopies performed under HFNO during the years the years 2018-2019.

Description

Inclusion Criteria:

  • major patients receiving panendoscopy
  • patients ventilated by face mask during the first period,
  • patients receiving oxygen by HFNO during the second period

Exclusion Criteria:

  • Patients receiving ventilatory strategy other than those selected by time period.
  • Patients receiving panendoscopies performed with a method of oxygenation other than those defined in their period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
FaceMask Ventilation (FMV)
During the period from January 1, 2015, to December 31, 2016, all panendoscopies performed with FMV, whether urgent or scheduled and regardless of indication, were included. Panendoscopies performed with any other oxygenation method were excluded.
HFNO
During the period from January 1, 2018, to December 31, 2019, all panendoscopies performed with HFNO, urgent or scheduled and regardless of indication, were included. Panendoscopies performed with any other oxygenation method were excluded.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients with oxygen desaturation
Time Frame: more than 1 minute during the intervention
Proportion of patients with oxygen desaturation (SpO2 < 90%) for more than 1 minute.
more than 1 minute during the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients requiring repeat face mask ventilation
Time Frame: more than 1 minute during the intervention
Proportion of patients requiring repeat face mask ventilation (at least one reventilation outside the initial denitrogenation)
more than 1 minute during the intervention
Proportion of patients requiring oro-tracheal intubation
Time Frame: during the intervention (max 6hours)from induction of anaesthesia to discharge from the operating theatre
Proportion of patients intubated during panendoscopy
during the intervention (max 6hours)from induction of anaesthesia to discharge from the operating theatre
Duration of the procedure
Time Frame: during the intervention (max 6hours) from induction of anaesthesia to discharge from the operating theatre
Time (minutes) from induction of anaesthesia to discharge from the operating theatre
during the intervention (max 6hours) from induction of anaesthesia to discharge from the operating theatre
Incidence of mild intraoperative complications
Time Frame: more than 1 minute during the intervention
Complications are : mild bradycardia (between 45 and 30 beats per minute), hypotension defined by MAP (between 65 and 40mmHg), hypercapnia (betaween 60 and 80 mmHg)
more than 1 minute during the intervention
Incidence of major intraoperative complications
Time Frame: more than 1 minute during the intervention
Complications are : Tracheotomy, extreme bradycardia < 30 beats per minute, hemodynamic instability defined by MAP < 40mmHg, hypercapnia (more than 80 mmHg)
more than 1 minute during the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 20, 2024

Primary Completion (Estimated)

October 30, 2024

Study Completion (Estimated)

November 30, 2024

Study Registration Dates

First Submitted

May 31, 2021

First Submitted That Met QC Criteria

October 23, 2022

First Posted (Actual)

October 25, 2022

Study Record Updates

Last Update Posted (Actual)

February 7, 2024

Last Update Submitted That Met QC Criteria

February 6, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • ID052021HFNO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ENT Tumor

Subscribe